--- title: "Century Therapeutics (IPSC) stock: news and investor profile" url: "https://aibio.space/companies/century-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Century Therapeutics, Inc. (NASDAQ: IPSC), United States. The directory classifies it as Biotechnology." --- IPSC Century Therapeutics, Inc. NASDAQ · United States # Century Therapeutics (IPSC) news Listings · 2025-08-29 ## [Century Therapeutics gets 180 more days to meet Nasdaq bid price rule](https://aibio.space/news/century-therapeutics-gets-180-more-days-meet-nasdaq-bid-price-rule/) Nasdaq gave Century until February 23, 2026, to lift its closing bid price above $1.00, and moved its listing to the Nasdaq Capital Market. The company's own clinical data for its lead lymphoma program did not meet its bar for a transformational result. ## Latest Century Therapeutics news 1. 2025-07-07 Distress [Century Therapeutics plans about 51% workforce cut as CFO and chief development officer leave](https://aibio.space/news/century-therapeutics-plans-about-51-percent-workforce-cut-cfo-chief/) Century Therapeutics (Nasdaq: IPSC) expects to cut headcount by approximately 51% and record about $3.7 million in severance charges. Its CFO and Chief Development Officer will leave in July 2025. ## Century Therapeutics at a glance - **Ticker**: IPSC - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $119.7 million ### Related companies - [Conexeu Sciences](https://aibio.space/companies/conexeu-sciences/) NASDAQ: CNXU - [SKYTECH ORION GLOBAL CORP.](https://aibio.space/companies/skytech-orion-global/) OTC: SKTG - [Cartesian Therapeutics](https://aibio.space/companies/cartesian-therapeutics/) NASDAQ: RNAC - [Cel-Sci](https://aibio.space/companies/cel-sci/) AMEX: CVM - [Life Stem Genetics](https://aibio.space/companies/life-stem-genetics/) OTC: LIFS - [Contineum Therapeutics](https://aibio.space/companies/contineum-therapeutics/) NASDAQ: CTNM - [Mineralys Therapeutics](https://aibio.space/companies/mineralys-therapeutics/) NASDAQ: MLYS - [Moderna](https://aibio.space/companies/moderna/) NASDAQ: MRNA ### Also on NASDAQ - [BioVie](https://aibio.space/companies/biovie/) BIVI - [ArriVent BioPharma](https://aibio.space/companies/arrivent-biopharma/) AVBP - [Oncolytics Biotech](https://aibio.space/companies/oncolytics-biotech/) ONCY - [China SXT Pharmaceuticals](https://aibio.space/companies/china-sxt-pharmaceuticals/) SXTC - [National Vision Holdings](https://aibio.space/companies/national-vision/) EYE - [Tarsus Pharmaceuticals](https://aibio.space/companies/tarsus-pharmaceuticals/) TARS ## What Century Therapeutics does Century Therapeutics, Inc. is a biotechnology company developing allogeneic, off-the-shelf cell therapies derived from induced pluripotent stem cells (iPSCs) for type 1 diabetes (T1D), other autoimmune diseases and cancer. Its platform combines iPSC differentiation know-how, CRISPR-mediated gene editing, its proprietary Allo-Evasion technology and manufacturing capabilities. Its beta islet, T cell and NK cell programs are built on this platform. CNTY-813 is a beta islet program for T1D, announced in November 2025, which has moved into IND-enabling studies, with an IND submission anticipated as early as 2026. CNTY-308 is a CD19-targeted CAR-iT cell therapy for B-cell-mediated diseases, also in IND-enabling studies, with clinical studies expected to start in 2026 after regulatory authorization. CNTY-101, a CAR-iNK cell therapy with six precision gene edits, is being prioritized in the CARAMEL investigator sponsored trial in B-cell-mediated autoimmune diseases, sponsored by Friedrich-Alexander University Erlangen-Nürnberg. Investigators presented initial CARAMEL data in December 2025. | Product or program | What it is | Stage | |---|---|---| | CNTY-813 | iPSC-derived beta islet cell therapy for type 1 diabetes | IND-enabling studies; IND anticipated as early as 2026 | | CNTY-308 | CD19-targeted CAR-iT cell therapy for B-cell-mediated diseases | IND-enabling studies | | CNTY-101 | CAR-iNK cell therapy with six precision gene edits for B-cell-mediated autoimmune diseases | Investigator sponsored trial (CARAMEL), enrolling and dosing | Summarised from the company's [10-K filed Mar 12, 2026](https://www.sec.gov/Archives/edgar/data/1850119/000110465926026759/ipsc-20251231x10k.htm). ## Century Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$109.2 million](https://www.sec.gov/Archives/edgar/data/1850119/000110465926026759/) | [$6.6 million](https://www.sec.gov/Archives/edgar/data/1850119/000110465926026759/) | | Net income (loss) | [-$9.6 million](https://www.sec.gov/Archives/edgar/data/1850119/000110465926026759/) | [-$126.6 million](https://www.sec.gov/Archives/edgar/data/1850119/000110465926026759/) | | Cash from operations | [-$103.9 million](https://www.sec.gov/Archives/edgar/data/1850119/000110465926026759/) | [-$110.1 million](https://www.sec.gov/Archives/edgar/data/1850119/000110465926026759/) | | Cash and equivalents | [$61.9 million](https://www.sec.gov/Archives/edgar/data/1850119/000110465926094523/) | [$58.4 million](https://www.sec.gov/Archives/edgar/data/1850119/000110465926026759/) | | Short-term investments | [$55.3 million](https://www.sec.gov/Archives/edgar/data/1850119/000110465926094523/) | [$130.9 million](https://www.sec.gov/Archives/edgar/data/1850119/000110465926026759/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $49.6 million, plus short-term investments of $70.1 million, $119.7 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Century Therapeutics What is the ticker symbol of Century Therapeutics? Century Therapeutics, Inc. trades under the ticker IPSC on NASDAQ. Where is Century Therapeutics listed? Century Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Century Therapeutics? The SEC Central Index Key (CIK) for Century Therapeutics, Inc. is 1850119. Its filings are on SEC EDGAR. How many shares does Century Therapeutics have outstanding? 181,075,321 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Century Therapeutics listed under? Our directory records Century Therapeutics, Inc. under United States. What does Century Therapeutics do? Our directory classifies Century Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Century Therapeutics? The ISIN recorded for Century Therapeutics, Inc. is US15673T1007. Does aibio.space cover Century Therapeutics? aibio.space lists Century Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Century Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Century Therapeutics develop? Century Therapeutics, Inc. is a biotechnology company developing allogeneic, off-the-shelf cell therapies derived from induced pluripotent stem cells (iPSCs) for type 1 diabetes (T1D), other autoimmune diseases and cancer. Its platform combines iPSC differentiation know-how, CRISPR-mediated gene editing, its proprietary Allo-Evasion technology and manufacturing capabilities. What is CNTY-813 from Century Therapeutics? CNTY-813: iPSC-derived beta islet cell therapy for type 1 diabetes Stage: IND-enabling studies; IND anticipated as early as 2026. What is CNTY-308 from Century Therapeutics? CNTY-308: CD19-targeted CAR-iT cell therapy for B-cell-mediated diseases Stage: IND-enabling studies. What was Century Therapeutics's revenue last year? $109.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Century Therapeutics profitable? Century Therapeutics, Inc. reported a net loss of $9.6 million for the fiscal year ended Dec 31, 2025, and used $103.9 million of cash in operations, per its annual report to the SEC. How much cash does Century Therapeutics have? $119.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Century Therapeutics Members talk about Century Therapeutics (IPSC). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Century Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-06-12 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1850119/000110465926073429/tm2617728d1_8k.htm) 2. 2026-03-26 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1850119/000110465926035255/tm269927-1_424b5.htm) 3. 2026-01-23 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1850119/000110465926006236/tm263921d1_8k.htm) 4. 2026-01-08 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1850119/000110465926001952/tm262422d2_ex99-1.htm) 5. 2025-12-02 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1850119/000110465925117704/tm2531763-4_def14a.htm) 6. 2025-11-21 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1850119/000110465925114992/tm2531763-3_pre14a.htm) 7. 2025-08-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1850119/000110465925085658/tm2524509d1_8k.htm) 8. 2025-07-07 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02). [Source](https://www.sec.gov/Archives/edgar/data/1850119/000110465925066091/tm2519717d1_8k.htm) 9. 2025-02-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1850119/000110465925019145/tm257938d1_8k.htm) 10. 2024-12-13 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1850119/000110465924128491/tm2431062d1_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:IPSC on TradingView](https://www.tradingview.com/symbols/NASDAQ-IPSC/). ## SEC filings and registration - **SEC name**: Century Therapeutics, Inc. - **CIK**: 1850119 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: IPSC (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 25 N 38TH STREET, 12TH FLOOR, PHILADELPHIA, PA - **Phone**: 215-981-4000 - **Shares outstanding**: 181,075,321 as of 2026-08-03 (10-Q filed 2026-08-12) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1850119/000110465926113055/tm2626840d1_8k.htm) filed 2026-10-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1850119/000110465926106312/tm2625030d1_8k.htm) filed 2026-09-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1850119/000110465926094533/tm2622911d1_8k.htm) filed 2026-08-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1850119/000110465926094523/ipsc-20260630x10q.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1850119/000110465926074577/tm2617925d1_8k.htm) filed 2026-06-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1850119/000110465926073429/tm2617728d1_8k.htm) filed 2026-06-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1850119/000110465926071383/tm2617028d1_8k.htm) filed 2026-06-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1850119/000110465926059824/tm2614312d1_8k.htm) filed 2026-05-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001850119), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Century Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker IPSC, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Century Therapeutics, Inc. - **Ticker**: IPSC - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US15673T1007 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-IPSC/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/century-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Century Therapeutics (IPSC) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/century-therapeutics/